BioSpace News Archive

NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will report financial results for the first quarter of 2021 before market open on Thursday, June 3, 2021.

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Food and Drug Administration (US FDA) has provided details of the additional information it is requesting regarding its Chimeric Antigen Receptor-T cell therapy

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced an investigator-initiated study to be conducted at Tampa General Hospital to evaluate the use of DSUVIA for patients with sickle cell disease presenting to the emergency department (ED) with painful vaso-occlusive crisis

Shuttle Pharmaceuticals Holdings, Inc., (Shuttle Pharma) a clinical stage company developing drugs to improve the treatment of cancer patients undergoing radiation therapy is pleased to announce the addition of Chris Senanayake , PhD as a member of its Board of Directors.

The new business is uniquely positioned to continue delivering research solutions for COVID-19 and beyond with community presence, data capabilities and health care expertise

Syngenta Group announced today that Daniel Vennard, former Global Director at the World Resources Institute, will join as Chief Sustainability Officer on July 26, 2021. He will be based in Basel, Switzerland, reporting to CEO Erik Fyrwald.

Highlights of Recent Positive Data from Nyxol’s Phase 3 Registration Trial Roundtable Discussion by 3 KOLs with Unique Perspectives and Distinct Patient Populations Webinar on Wednesday, May 26 th @ 1:00 pm EDT

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will present at the William Blair 41st Annual Growth Stock Conference on Thursday, June 3, 2021 at 3:20 p.m. Central / 4:20 p.m. Eastern / 1:20 p.m. Pacific.

Soligenix, Inc. (Nasdaq: SNGX) announced today that the Japan Patent Office has allowed the patent application titled “Systems and Methods for Producing Synthetic Hypericin”.

MindMed, a leading clinical stage psychedelic medicine company, announced the approval by the local Swiss ethics committee of the first clinical trial evaluating the acute effects of different doses of mescaline and the role of the serotonin 5-HT2A receptor in mescaline-induced altered states of consciousness.